Spyre Therapeutics (NASDAQ:SYRE) Given New $40.00 Price Target at Wells Fargo & Company

Spyre Therapeutics (NASDAQ:SYREFree Report) had its price target raised by Wells Fargo & Company from $35.00 to $40.00 in a research note issued to investors on Monday morning, Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other research firms have also commented on SYRE. Stifel Nicolaus lifted their target price on shares of Spyre Therapeutics from $36.00 to $54.00 and gave the stock a buy rating in a report on Tuesday, March 26th. BTIG Research upped their price objective on Spyre Therapeutics from $32.00 to $40.00 and gave the company a buy rating in a report on Friday. Finally, Robert W. Baird began coverage on Spyre Therapeutics in a research note on Thursday, May 2nd. They issued an outperform rating and a $50.00 target price on the stock. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of Buy and a consensus target price of $43.17.

Read Our Latest Stock Report on SYRE

Spyre Therapeutics Price Performance

Shares of SYRE stock opened at $37.00 on Monday. Spyre Therapeutics has a 1 year low of $2.66 and a 1 year high of $47.97. The business’s 50 day moving average is $37.10. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of -0.52 and a beta of 2.93.

Spyre Therapeutics (NASDAQ:SYREGet Free Report) last released its earnings results on Thursday, February 29th. The company reported ($2.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($1.80). Equities research analysts anticipate that Spyre Therapeutics will post -2.36 earnings per share for the current year.

Spyre Therapeutics Company Profile

(Get Free Report)

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).

Featured Articles

Analyst Recommendations for Spyre Therapeutics (NASDAQ:SYRE)

Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.